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EDITORIALIntroducing the New Value in Health Regional Issues Journal:
The Latin America Region EditionThese are exciting times for the Latin American region. Our
region has developed steadily in the recent years and has a
promising outlook in the current international climate. It appears
that there is momentum for countries in the region to design
long-term development strategies. There has been a gradual
consolidation and strengthening of our democracies, and most
of the region has adequately resisted the economic and financial
crisis with responsible macroeconomic measures and structural
reform [1]. Annual gross domestic product growth averaged 4.3%
during 2010 to 2011 [2]. Health indicators, as well as health care
coverage and provision, have also been improving, with some of
our countries approaching universal health coverage. For exam-
ple, life expectancy at birth has now risen to 74.8 years, and the
infant mortality rate has declined to 15.5 per 1000 live births [2].
In the field of outcomes research, health economics, and
health technology assessment (HTA), there have also been sig-
nificant advances in our region since we published the Value in
Health 1st Special Issue: Pharmacoeconomics and Outcomes Research in
Latin America about a year and a half ago [3]. Some regionwide
examples are a recent resolution signed in September 2012 at the
28th Pan American Sanitary Conference (‘‘Health technology
assessment and incorporation into health systems,’’ CSP28/11)
promoting the institutionalization of HTA for supporting
informed decision making in our countries, or the still young
REDETSA (HTA Network of the Americas) founded in 2011, which
brings together the main government and academic institutions
working in this field in the Americas [4].
This very young journal, Value in Health Regional Issues, and the
current issue devoted to the Latin American region, comes in
these exciting times, which are also reflected in a recently
launched newsletter of the ISPOR Latin America Consortium [5]
as well as the recent HTAi regional meeting held in Colombia in
the context of the launch of the new Colombian Health Technol-
ogy Institute [6]. In 2013, after having published the new Value in
Health Regional Issues for Latin America, the ISPOR 4th Latin
America Conference will be held in Buenos Aires [7].
The current issue (December 2012) features regionwide arti-
cles as well as studies from six Latin American countries that
provide new evidence or ideas extending the current knowledge
base regarding the value of health care interventions particular to
the region. This first issue reflects the dynamic growth in the field
with articles on economic evaluation (such as a burden of disease
study on dengue in Colombia [8]); health policy studies thatial support: The authors have no other financial rprovide updates on the policy situation in several Latin American
countries [9]; patient-reported outcomes studies (such as a
population-based depression study in Brazil [10]); conceptual
articles showing the influence that regionwide initiatives can
have on decision making in the field of vaccines [11]; and
commentaries discussing social values and decision making
(such as those in the Mexican environment [12,13]). We present
studies that span a wide spectrum of health technologies, from
screening and primary prevention to palliative and intensive
care; from drugs to diagnostic tests and devices.
We hope that readers interested in improving health in our
region—from researchers and decision makers to technology
producers and users—find this issue as informative and enrich-
ing as we do. I hope that the region, together with this journal,
continues to improve with time. And last but not the least, a
special thanks to the authors, journal coeditors, and ISPOR staff
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